度普利尤单抗在中重度特应性皮炎患者中的长期安全性和有效性:3期开放标签扩展研究
这是一项正在进行的多中心开放标签扩展研究(NCT01949311),评估度普利尤单抗在既往参加过1至3期临床试验的成人中重度特应性皮炎患者中的长期治疗。患者每周接受300 mg度普利尤单抗,最长治疗76周(数据截止2016年4月)。安全性是主要结局,同时评估有效性。共纳入1491例患者(1042.9患者年),92.9%在截止时仍在治疗。安全性特征与既往报告试验一致(420.4不良事件/100患者年,8.5严重不良事件/100患者年),无新安全信号;常见不良事件包括鼻咽炎、结膜炎和注射部位反应。所有疗效结局(包括皮肤炎症、瘙痒和生活质量)在76周内持续改善。局限性包括缺乏对照组、治疗76周或更长的患者数量有限(中位随访24周)以及患者未接受批准的300 mg每2周剂量方案。结论支持度普利尤单抗作为中重度特应性皮炎的连续长期治疗。
要点
- 度普利尤单抗300 mg每周长期治疗中重度特应性皮炎安全性特征与既往试验一致,无新安全信号。
- 常见不良事件包括鼻咽炎、结膜炎和注射部位反应。
- 疗效在76周内持续改善,包括皮肤炎症、瘙痒和生活质量。
核心结论
- 度普利尤单抗的安全性和有效性特征支持其作为中重度特应性皮炎的连续长期治疗。
研究设计与样本
- 正在进行的多中心开放标签扩展研究(NCT01949311),纳入1491例既往参加过1至3期临床试验的成人中重度特应性皮炎患者,每周给予度普利尤单抗300 mg,最长治疗76周(数据截止2016年4月)。
主要发现
- 安全性特征与既往报告试验一致:420.4不良事件/100患者年,8.5严重不良事件/100患者年,无新安全信号。
- 常见不良事件包括鼻咽炎、结膜炎和注射部位反应。
- 所有疗效结局(包括皮肤炎症、瘙痒和生活质量)在76周内持续改善。
临床怎么用
- 该研究支持度普利尤单抗用于中重度特应性皮炎的长期连续治疗。
局限性
- 缺乏对照组。
- 治疗76周或更长的患者数量有限(中位随访24周)。
- 患者未接受批准的300 mg每2周剂量方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Significant unmet need exists for long-term treatment of moderate to severe atopic dermatitis (AD). OBJECTIVE: To assess the long-term safety and efficacy of dupilumab in patients with AD. METHODS: This ongoing, multicenter, open-label extension study (NCT01949311) evaluated long-term dupilumab treatment in adults who had previously participated in phase 1 through 3 clinical trials of dupilumab for AD. This analysis examined patients given 300 mg dupilumab weekly for up to 76 weeks at data cutoff (April 2016). Safety was the primary outcome; efficacy was also evaluated. RESULTS: Of 1491 enrolled patients (1042.9 patient-years), 92.9% were receiving treatment at cutoff. The safety profile was consistent with previously reported trials (420.4 adverse events/100 patient-years and 8.5 serious adverse events/100 patient-years), with no new safety signals; common adverse events included nasopharyngitis, conjunctivitis, and injection-site reactions. Sustained improvement was seen up to 76 weeks in all efficacy outcomes, including measures of skin inflammation, pruritus, and quality of life. LIMITATIONS: Lack of control arm, limited number of patients with 76 weeks or longer of treatment (median follow-up, 24 weeks), and patients not receiving the approved dose regimen of 300 mg every 2 weeks. CONCLUSION: The safety and efficacy profile from this study supports the role of dupilumab as continuous long-term treatment for patients with moderate to severe AD.
引用
- Deleuran M, Thaçi D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2019. PMID: 31374300. doi:10.1016/j.jaad.2019.07.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。